How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?
Emanuele Crocetti, Orietta Giuliani(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Ravaioli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Silvia Mancini(University of Florence), Fabio Falcini(Centro di Riferimento Oncologico), Benedetta Vitali, Flavia Baldacchini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Federica Zamagni(Cancer Institute (WIA)), Rosa Vattiato(Cancer Institute (WIA)), Lauro Bucchi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 1
Related Papers
Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001
|British Journal of Dermatology|2004|241
Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy
|British Journal of Cancer|1998|140
European Cancer Information System
|Unknown|2018|109
All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980–2018)
|Environmental Health|2024|59
Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study
|Clinical Gastroenterology and Hepatology|2022|31